Chemotherapy and COVID-19 Vaccination in Patients With Gastrointestinal Cancer

Background/Aim: Multiple doses of vaccines against the coronavirus disease (COVID-19) provide patients with cancer the opportunity to continue cancer treatment. This study investigated the safety and efficacy of COVID-19 vaccination in patients with cancer and the optimal timing of vaccination during chemotherapy. Patients and Methods: A total of 131 patients with gastrointestinal (GI) cancer who received two doses of the COVID-19 vaccine were included in this study. This study combined two cohorts: an evaluation cohort of 79 patients receiving chemotherapy and a control cohort of 52 patients under follow-up after radical surgery. None of the patients had any history of COVID-19. Treatmentand vaccine-related adverse events (AEs) were recorded through outpatient interviews and self-reports. Results: In the evaluation cohort, 62 patients (78.4%) experienced vaccinerelated AEs after the first dose, and 62 patients (78.4%) experienced vaccine-related AEs with an increased rate of fever and fatigue after the second dose. In the control cohort, vaccine-related AEs occurred in 28 (53.8%) patients after the first dose and in 37 (71.2%) patients after the second dose, with increased fever and fatigue after the second dose. Of the 79 patients, 49 received chemotherapy before vaccination. Twelve patients (24.5%) changed their treatment schedule:four for safety reasons, four for myelosuppression, and four for convenience. Three patients discontinued the treatment because of disease progression. Conclusion: Systemic chemotherapy in patients with GI cancer does not have a markedly negative effect on COVID-19 vaccination, resulting in manageable vaccine -related AEs, and minimizing the need for treatment schedule changes.